Post-effective amendment to a registration statement that is not immediately effective upon filing

Commitments and Contingencies (Details)

v3.22.1
Commitments and Contingencies (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jan. 10, 2022
Jul. 27, 2021
Jul. 01, 2021
Mar. 28, 2021
Dec. 31, 2021
Dec. 31, 2020
Oct. 09, 2020
Commitments and Contingencies [Line Items]              
Rent expense         $ 100 $ 100  
Allowance for doubtful accounts           257  
Accrued settlement expense           39,486  
Additional settlement liability       $ 21,400 $ 21,366 39,486  
Number of shares issued upon exercise of warrants   1,833,596     516,025    
Proceeds from issuance of common stock for exercise of warrant   $ 9,200     $ 16,699    
Prepaid expenses and other current assets         5,109 240  
GEM Warrant [Member]              
Commitments and Contingencies [Line Items]              
Warrant issued       3,329,812      
Exercise price of warrant       $ 3.19      
Warrants to purchase shares       1,496,216      
Warrants to purchase shares, amount       $ 7,500      
Warrants expire period       The GEM Warrant was valid for a period of three years from the date NeuroRx’s stock is listed for trading on a national securities exchange or consummation of a reverse merger transaction of the type contemplated by the Merger Agreement.      
Accrued settlement expense           $ 39,500  
Reimbursements from Relief Therapeutics Holding AG              
Commitments and Contingencies [Line Items]              
Payment to related party         $ 10,900    
Phase II Inhaled clinical trial of Aviptadil              
Commitments and Contingencies [Line Items]              
Research commitments     $ 7,400        
GEM Share Subscription Facility Agreement              
Commitments and Contingencies [Line Items]              
Share subscription agreement term         3 years    
Share subscription value         $ 95,600    
Commitment fee         1,900    
Relief Therapeutics Collaboration Agreement Breach [Member]              
Commitments and Contingencies [Line Items]              
Invoiced costs $ 185,000            
Polypeptide [Member]              
Commitments and Contingencies [Line Items]              
Purchase commitments             $ 5,300
Prepaid expenses and other current assets         3,300    
Sponsored Research Agreement [Member]              
Commitments and Contingencies [Line Items]              
Research commitments         400    
Research commitments paid         $ 300